Prosight Management Invests $10 Million in Nektar Therapeutics Ahead of Key Phase 3 Launch
On May 15, 2026, Prosight Management disclosed a purchase of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR), valued at approximately $10.27 million based on quarterly average pricing. The firm increased its stake in the biopharmaceutical company ahead of an important Phase 3 launch.
Tickers: $NKTR
Topics: biopharmaceuticals institutional investing stock ownership disclosure